Azione STAB STATERA BIOPHARMA, INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Statera Biopharma, Inc.

Azioni

STAB

US8575611046

Prezzo di chiusura OTC Markets
Altri mercati azionari
 00:00:00 29/04/2024 		Variaz. 5gg Var. 1 gen.
0,0007 USD -.--% Grafico intraday di Statera Biopharma, Inc. -.--% +16,67%
2022 Statera Biopharma, Inc. riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 30 settembre 2022 CI
2022 Statera Biopharma, Inc. riporta i risultati degli utili per il secondo trimestre e i sei mesi conclusi il 30 giugno 2022 CI

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Statera Biopharma : Material Agreement - Form 8-K
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
STATERA BIOPHARMA, INC. : Other Events (form 8-K)
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data
Top Premarket Gainers
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione STAB
  4. Notizie Statera Biopharma, Inc.
  5. Altre lingue